KNSA — Kiniksa Pharmaceuticals International Share News
0.000.00%
Last trade - 00:00- $6.24bn
- $5.71bn
- $677.56m
Kiniksa Pharmaceuticals Ltd expected to post a loss of 65 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Ltd Announces Launch Of Arcalyst Named Patient Program
Kiniksa Pharmaceuticals slides after quarterly update
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in June - Earnings Summary
Kiniksa Pharmaceuticals Ltd expected to post a loss of 79 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Abercrombie & Fitch, Antero Midstream, Wendy's
Brief: Kiniksa Announces Issuance Of U.S. Patent For Treatment Of Recurrent Pericarditis
Brief: Kiniksa Outlines Next Steps For The Development Of Mavrilimumab
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Ingersoll Rand, InMode, Signet Jewelers
Kiniksa: Rises as COVID-19 drug succeeds mid-stage study
Brief: Kiniksa Announces Positive Results For Mavrilimumab Phase 2 Trial In Non-Mechanically Ventilated Severe Covid-19 Patients
Brief: Kiniksa Pharmaceuticals Announces Commercial Availability Of Arcalyst For Recurrent Pericarditis
U.S. STOCKS ON THE MOVE-Kiniksa Pharma, Tonix, Construction Partners
U.S. STOCKS ON THE MOVE-Alcoa Corp, Idera Pharma, Kiniksa Pharma
Kiniksa Pharma: Up after FDA approves heart inflammation treatment
Brief: FDA Approves Arcalyst Injection To Treat Recurrent Pericarditis, Reduce Risk Of Recurrence
Brief: Kiniksa Pharmaceuticals Ltd Says Kiniksa Uk Entered Into A Commercial Supply Agreement With Regeneron On March 1, 2021
Brief: Kiniksa Launches Patient Registry (Resonance) For Recurrent Pericarditis